ziconotide and Motor-Neuron-Disease

ziconotide has been researched along with Motor-Neuron-Disease* in 1 studies

Other Studies

1 other study(ies) available for ziconotide and Motor-Neuron-Disease

Article	Year
Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report. A&A practice, 2019, Jul-01, Volume: 13, Issue:1 Spasticity can be very debilitating and painful. We present a case of severe spasticity from primary lateral sclerosis refractory to intrathecal baclofen in doses up to 1100 μg/d. Baclofen was weaned down and switched to intrathecal ziconotide at 0.6 μg/d. The dose was then titrated up to 3 μg/d with excellent control of spasticity. This case suggests that low-dose intrathecal ziconotide should be considered in patients with lower extremity spasticity refractory to intrathecal baclofen. Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Motor Neuron Disease; Muscle Spasticity; omega-Conotoxins; Pain; Treatment Outcome	2019

Article

Year

Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report.

A&A practice, 2019, Jul-01, Volume: 13, Issue:1

Spasticity can be very debilitating and painful. We present a case of severe spasticity from primary lateral sclerosis refractory to intrathecal baclofen in doses up to 1100 μg/d. Baclofen was weaned down and switched to intrathecal ziconotide at 0.6 μg/d. The dose was then titrated up to 3 μg/d with excellent control of spasticity. This case suggests that low-dose intrathecal ziconotide should be considered in patients with lower extremity spasticity refractory to intrathecal baclofen.

Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Motor Neuron Disease; Muscle Spasticity; omega-Conotoxins; Pain; Treatment Outcome

2019